Clinical trial
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With…
NCT00477412 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00477412 |
|---|---|
| Title | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma |
| Official title | Phase I/II Study of Bortezomib (VELCADE) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Mantle Cell Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | Bortezomib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Rituximab, Vincristine |
| Enrollment | 107 |
| Start date | Apr 3, 2007 |
| Primary completion | Oct 28, 2020 |
| Completion | Oct 28, 2020 |
| First posted | May 23, 2007 |
| Last update posted | Jan 28, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: